论文部分内容阅读
目的探讨国产紫杉醇及长春瑞滨加顺铂联合治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法选取初治晚期NSCLC 76例,分别应用TP(国产紫杉醇+顺铂)、NP(长春瑞滨+顺铂)方案治疗。每例均完成2周期化疗后评价疗效及其不良反应。结果两组患者近期有效率分别为TP组36.1%、NP组35.0%,两组间有效率比较差异均无统计学意义(χ2=0.108.6,P>0.05)。TP组中位生存期8.9月,NP组中位生存期8.4月(P>0.05)。TP组1、2、3年生存率分别为40.0%、18.3%、5.0%;NP组1、2、3年生存率分别为39.0、16.9%、5.1%,两组间比较差异无统计学意义(χ2=0.1404,P>0.05)。两组不良反应均以骨髓抑制、脱发及恶心呕吐为主,但均未影响治疗。两组病例均无化疗相关死亡发生。结论 TP、NP联合方案是晚期NSCLC有效且耐受性较好的治疗方案。
Objective To investigate the efficacy and adverse reactions of domestic paclitaxel combined with vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 76 patients with advanced non-small cell lung cancer were enrolled in this study. TP (domestic paclitaxel + cisplatin) and NP (vinorelbine + cisplatin) regimen were used respectively. Each case was completed after 2 cycles of chemotherapy to evaluate the efficacy and adverse reactions. Results The effective rates of the two groups were 36.1% in the TP group and 35.0% in the NP group, respectively. There was no significant difference in the effective rates between the two groups (χ2 = 0.108.6, P> 0.05). The median survival time in TP group was 8.9 months, and the median survival time in NP group was 8.4 months (P> 0.05). The 1-year, 2-year and 3-year survival rates of TP group were 40.0%, 18.3% and 5.0% respectively. The 1, 2 and 3-year survival rates of NP group were 39.0,16.9% and 5.1% respectively, with no significant difference between the two groups (χ2 = 0.1404, P> 0.05). Two groups of adverse reactions were bone marrow suppression, hair loss and nausea and vomiting, but did not affect the treatment. No chemotherapy-related death occurred in both groups. Conclusion TP and NP combination regimens are effective and well tolerated treatment for advanced NSCLC.